This study compared the diagnostic accuracy of the measurement of serum cardiac troponin I (cTnI) with creatine kinase (CK) MB mass in patients with minor myocardial injury whose measured total CK activity did not exceed twice the upper reference limit (300 U/L for men; 200 U/L for women). Forty-eight consecutive patients presenting with chest pain and with in-hospital documentation of myocardial injury were enrolled. Electrocardiogram, echocardiogram, and serial serum CK-MB mass, cTnI, and total CK were measured over 36 h after admission. Peak total CK activity was within normal limits in 28 patients (58%). The mean (؎SD) peak CK-MB mass and cTnI concentrations were: 16.4 (11.8) g/L and 132 (13.0) g/L; respectively. The peak biochemical marker index (defined as CK-MB or cTnI divided by its respective upper reference limit) was significantly (P <0.05) higher for cTnI than for CK-MB from 7 to 36 h. The clinical sensitivity for detection of myocardial injury for cTnI was 100% [95% confidence interval (CI): 87.2% to 100%], compared with 81.8% (CI: 67.3% to 91.8%) for CK-MB. Thus, cTnI was more sensitive than CK-MB mass for detection of myocardial injury in patients with small increases of total CK.
Currently, the biochemical diagnosis of acute myocardial infarction (AMI) 2 is confirmed by observing a serial rise and fall in the serum activity of creatine kinase (CK) and its MB isoenzyme (CK-MB) [1] . Although the use of these enzyme markers enjoys widespread acceptance, both CK and CK-MB have deficiencies. First, both CK and CK-MB are present in tissues other than the myocardium. A serial rise and fall of these enzymes can be observed with conditions other than AMI [2, 3] . Second, it is now recognized that profound ischemic cardiac injury can occur without myocardial necrosis and the release of CK and CK-MB can occur without infarction [4] . Confusion therefore exists with respect to the enzymatic diagnosis of AMI, especially when release of CK and CK-MB is minimal. The diagnostic problem in AMI with an increased CK-MB in the absence of abnormally increased total CK has challenged clinicians for decades [5] . As a result, the definition of an AMI varies widely among physicians, hospitals, and countries. Recently, two new markers have become available for detection of myocardial injury. Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) offer improved specificity and sensitivity for detection of acute myocardial injury when compared with CK-MB in patients with suspected acute myocardial injury [3, 6, 7] . In this study, we prospectively compared serum cTnI with CK-MB mass measurements in patients with minor ischemic myocardial injury on the basis of minimal increases of total CK activity and electrocardiography or echocardiography findings.
Materials and Methods
This study was conducted at the Hennepin County Medical Center, a 450-bed teaching hospital that provides acute care for the city of Minneapolis, MN. Over an 8-month period we identified 48 consecutive patients with a diagnosis of acute minor ischemic myocardial injury. We defined minor ischemic myocardial injury as follows: (a) chest discomfort suggestive of acute myocardial ischemia, (b) peak total CK activity less than twice the upper reference limit (300 U/L for men; 200 U/L for women), and either (c) electrocardiogram (ECG) alterations indic-ative of ischemic injury or evolving AMI, defined as ST-segment deviations (ST-segment depression or elevation Ն0.1 mV on at least two contiguous leads) or new symmetric T-wave inversions Ն0.1 mV, or both, or (d) two-dimensional echocardiogram (echo) alterations indicative of a new or presumably new regional wall motion abnormality. All patients were assessed by detailed clinical examination during a 24 -72-h period after admission. Patients were not included if they had a peak total CK activity Ͼ600 U/L or had fewer than two blood samples drawn. All the biochemical measurements vs time were based on onset of chest pain.
Serial ECGs were performed on admission and thereafter at least once daily for all patients. ECGs were evaluated by an experienced cardiologist who was unaware of the biochemical marker results. A two-dimensional echo was recommended but not required for all patients. Coronary arteriograms were obtained at the discretion of the attending clinician and were not a criterion for this study.
Clotted blood samples (serum) for analysis of CK-MB mass and cTnI were obtained at admission and every 6 -8 h for 36 h. The concentration of CK-MB was measured on the Stratus II analyzer (Dade International) by a mass immunoassay on the basis of a monoclonal antibody that specifically recognizes CK-MB [8] . The lower limit for detection of CK-MB was 1.0 g/L. Imprecision (CV) was 4.8% at the upper reference limit of 5.0 g/L. cTnI also was measured on the Stratus II analyzer (Dade International) by a mass immunoassay that uses two monoclonal antibodies specific for independent epitopes of cTnI [9] . The lower limit for detection of cTnI was 0.35 g/L. Imprecision (CV) was 9.5% at the upper reference limit of 0.8 g/L. Total CK activity was measured at 37°C on a Vitros analyzer with a kinetic enzymatic method (Johnson and Johnson Co.). The upper reference limits for total CK had been determined nonparametrically, stratified for men and women of mixed race, who were hospitalized without cardiac pathology. The biochemical marker index was defined as and calculated from the measured serum marker concentration divided by the upper reference limit (i.e., CK-MB concentration/5.0; cTnI concentration/0.8).
Statistical comparisons of cTnI and CK-MB data were analyzed by one-way and two-way analyses of variance. Results are reported as mean Ϯ 95% confidence intervals (bars on graphs) and SD. The level of significance was set at 0.05.
Results
Between October 1995 and May 1996 we identified 48 consecutive patients with a diagnosis of acute minor ischemic myocardial injury, 27 (54%) men and 21 (46%) women (Table 1 ). The mean age was 65 years (range 33-96 years). The mean KILLIP class was 1.3 (range 1-3). Electrocardiographic evidence of myocardial ischemia was present in 39 (81%) of the 48 patients. The ischemic change was ST-segment depression in 13 patients, ST-segment elevation in 17 patients, T-wave inversion in 13 patients, and combined T-wave inversion and ST-segment deviation in 6 patients. New Q-waves evolved in 5 patients. A two-dimensional echo was performed in 43 (90%) of the patients. In 32 patients the echo revealed a presumed new regional wall motion abnormality. This involved the anterior wall (n ϭ 16), the inferior wall (n ϭ 14), or the posterior wall (n ϭ 2). In 5 patients no echo was performed because of previously known ischemic cardiomyopathy; however, all showed evidence of ischemic injury by ECG. Coronary arteriograms were obtained in 30 of the 48 patients (62.5%). Twenty-seven of the 30 (90%) arteriograms demonstrated 90 -100% occlusion in at least one coronary artery, indicating that coronary artery disease was present. Eighteen of these were in patients whose total CK peaked within the reference range. Arteries in the other three patients demonstrated 20%, 40%, and 70% occlusions by angiography.
A summary of biochemical findings together with ECG and echo findings for all patients is presented in Table 1 . The peak CK activity was within normal limits in 28 (58%) patients. The mean (ϮSD) peak CK was 282 Ϯ 144 U/L (range 55-584 U/L). The mean peak CK-MB was 16.4 Ϯ 11.8 g/L (1.2-52.5 g/L). The mean peak cTnI was 13.2 Ϯ 13.0 g/L (0.4 -47.7 g/L). The peak cTnI concentrations correlated significantly with the peak CK-MB concentration (P Ͻ0.0001; r ϭ 0.58) and peak total CK activity (P ϭ 0.002; r ϭ 0.45). As shown in Fig. 1 , within each biochemical marker index group, cTnI was significantly increased (P Ͻ0.01) at all time periods compared with the values at 0 -6 h, whereas CK-MB was increased significantly only at 7-12 h (P Ͻ0.01) and 13-18 h (P Ͻ0.05) compared with the values at 0 -6 h. Between groups, the cTnI index was increased significantly (P Ͻ0.05-0.001) compared with CK-MB from 7 to 36 h after the onset of chest pain (Fig. 1) . The clinical sensitivities (defined as the number of patients with increased activity above the upper reference limit compared with all 48 patients) with 95% confidence intervals of cTnI and CK-MB at each time period following onset of chest pain are shown in Table 2 . Neither marker was a good early indicator of myocardial injury at Ͻ6 h (sensitivities Ͻ40%); however, the sensitivity of cTnI at 7-36 h after the onset of chest pain was 88 -100%, a substantial improvement over CK-MB (sensitivity 61-81%).
Discussion
During the past two decades, several studies have described the entity called microinfarction or non-Q-wave infarction, characterized by an increased CK-MB in the presence of normal total CK [5] . Retrospective review of these studies reveals frequent clinical indicators of infarction (documented by ECG and echo) with the above enzyme pattern occurring more commonly in older patients. Further, because the ECG is nondiagnostic in 50% of patients with AMI, the confirmation of the diagnosis often requires the quantitative detection of CK-MB [1] .
Our study presents unique data regarding the sensitive detection of minor ischemic myocardial injury with the use of serial measurements of cTnI in 48 consecutive patients with minimal increase of total CK activity within 36 h after the onset of chest pain. Determinations of both cTnI and CK-MB mass within several time frames over 36 h after onset of chest pain demonstrated cTnI to have higher clinical sensitivity (100%) than CK-MB mass did Clinical Chemistry 43, No. 11, 1997 (82%) ( Table 2 ). Further, within each time frame after 6 h, the cTnI index was significantly increased compared with CK-MB (Fig. 1) . Thus, our data suggest that detection of myocardial injury during the course of minor ischemic injury may be facilitated by the measurement of serum cTnI.
The definition of an AMI on the basis of enzyme criteria (total CK and CK-MB) varies widely, both in the US and internationally. Many investigators have required the total CK activity to exceed twice normal before establishing the diagnosis of an AMI [10] . In our study of patients that display clinical evidence for myocardial injury (Table 1) , an increased total CK activity less than twice the upper limit of the reference interval accounted for 42% of the study population, with the other 58% having normal total CK activities. Further, the cardiac catheterization findings documented that substantial coronary artery disease was present in our patient study group, with 18 patients with peak total CK activities less than the upper reference limit demonstrating Ͼ90% coronary artery occlusion of at least one vessel.
Minor increases of cTnI or CK-MB can serve as markers for the occurrence of an episode of severe myocardial ischemia, regardless of whether they are indicative of reversible or irreversible injury [11] [12] [13] . Further, patients with minor ischemic myocardial injury who demonstrate a release of either CK-MB or cTnI are at increased risk for future MI and death. Thus, increases in biochemical markers may lead clinicians to certain types of treatment. A recent study examined the prognostic value of cTnI activity in patients with unstable angina or non-Q-wave MI [14] . The mortality rate at 42 days was significantly higher in the patients with measurable cTnI (Ն0.4 g/L) than in those with undetectable amounts (Ͻ0.4 g/L), thus providing useful prognostic information and permitting early identification of patients with an increased risk of death. Although the current study was limited because no patient follow-up data were obtained, our findings complemented the study of Antman et al. [14] . cTnI measurements have also been used for risk stratification of non-AMI patients admitted with chest pain [15] . With the use of odds ratios, Wu et al. [15] showed that poor outcomes were significantly more frequent in the increased serum cTnI group than in the normal serum cTnI group, a substantial improvement over CK-MB implications. Further, preliminary evidence has shown that increased serum cTnI could be used for screening and risk assessment in congestive heart failure patients [16] .
Our findings complement other studies that have demonstrated cTnI to be a very sensitive marker for AMI in patients admitted to intensive care units with a high probability of AMI, although we show cTnI not to be a sensitive early marker (Table 2 ) [17, 18] . The very low to undetectable cTnI values in serum from noncardiac diseased and apparently healthy patients permits use of very low discrimination values compared with higher values of CK-MB for the determination of myocardial injury. Despite the possibility that there may be other tissue sources of cTnI not yet understood, the apparent unique aspect of cTnI as being 100% tissue-specific for the myocardium [9] makes it an excellent marker to serve as a biochemical tool for detecting myocardial injury in serum as well as differentiating patients that often show falsely increased CK-MB concentrations. These include patients with chest trauma [19] , cocaine-associated chest pain [20] , criticalness in ill intensive care [21] , muscle trauma and disease [3] , and renal disease [22] . Increased cTnI amounts in patients with little or no clinical evidence suggestive of myocardial injury should alert the clinician to consider occult cardiac injury or disease. One limitation of the study design was that our population had a higher incidence of ischemic heart disease (as defined by ECG and echo findings and documented by angiography findings) and that our findings may not be easily extrapolated to larger patient populations. Another potential limitation of this study was its relatively small sample size; how- Within-group comparisons: *, P Ͻ0.05 vs 0 -6 h; †, P Ͻ0.01 vs 0 -6 h. Between-group comparisons: §, P Ͻ0.05 vs CK-MB; ‡, P Ͻ0.001 vs CK-MB. ever, our data add to growing literature supporting cTnI as the preferred marker compared with CK-MB for the detection of minor ischemic cardiac injury. These findings further demonstrate the need to reevaluate the use of a twofold increase of total CK activity as a criterion for AMI.
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